Jefferies London Healthcare Conference 2024

November 19, 2024

COPYRIGHT © ABCELLERA

DISCLAIMER

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

COPYRIGHT © ABCELLERA

We are a biotech with the ability to **make many antibody medicines**.

By integrating computation, engineering and biology, we have built a vertically integrated biotech that is capable of developing **differentiated antibody-based therapies** from **target to the clinic**.



COPYRIGHT © ABCELLERA

We built our engine through **partnerships**.

Since 2014, we have partnered with some of the industry's most innovative pharma and biotech companies. Partnerships were a driver for R&D, and provided near-term revenue in the form of research payments and long-term potential revenue in the form of royalty stakes in those drug programs.

100+
partnered-initiated therapeutic programs

14
molecules from partnered programs have reached the clinic



COPYRIGHT © ABCELLERA

We have a **portfolio of royalties** in future antibody medicines.

The value of this portfolio will mature over time as our partners advance these programs into the clinic and beyond.

Cumulative # of

PARTNER-INITIATED PROGRAM STARTS WITH DOWNSTREAMS*



Cumulative # of

MOLECULES IN THE CLINIC*



*As of September 30, 2024

COPYRIGHT © ABCELLERA

We are now using our engine to build an **internal pipeline** of potential **blockbuster medicines**.

12+ years

investment in technology, teams, and infrastructure

$500M+

platform investments, with integration from target to the clinic

Clinical manufacturing facility

on-track to come online late 2025



Capital allocation shifting

from building capabilities to using them



COPYRIGHT © ABCELLERA

We have the **capability** and **capital** to execute on our strategy.

Through our partnership work, revenue from COVID, and committed government funding, we have built the liquidity needed to build our pipeline of first-in-class and best-in-class medicines.

~$875M in available liquidity to execute on our strategy

~$670M in total cash, cash equivalents, & marketable securities

~$205M in total available government funding

COPYRIGHT © ABCELLERA

We're hunting for blockbusters and are **not limited to a single indication**.

What's most important now is which programs we pick.

Our engine can be applied broadly to the $400B* antibody therapeutics market.

Our strategy is to look broadly to find winning opportunities by asking the following questions:

* Market Size by 2030 *Source: IQVIA*

- Do we like the science?
- Is there a commercial opportunity with an unmet medical need?
- Is there an opportunity for differentiation?
- Is there a clear development path?

COPYRIGHT © ABCELLERA

We intend to submit **Clinical Trial Applications*** for our first **2 programs** in **Q2 2025**.

MOLECULE	TARGET	INDICATION	THERAPEUTIC AREA	POTENTIAL DIFFERENTIATION	STAGE
ABCL635	**undisclosed** GPCR or ion channel	**undisclosed**	**metabolic & endocrine conditions**	**first in class**	IND-ENABLING
ABCL575	**OX40L**	**atopic dermatitis**	**immunology & inflammation**	**best in class**	IND-ENABLING

* **Clinical Trial Applications (CTAs)** = Canadian equivalent to an **Investigational New Drug (IND) submission**

COPYRIGHT © ABCELLERA

We expect a number of key milestones in the next **18 to 24 months**.

2025 Q2

First 2 CTAs*

for ABCL635, ABCL575

2026

First 2 Readouts

on ABCL635, ABCL575

* **Clinical Trial Applications (CTAs)** = Canadian equivalent to an **Investigational New Drug (IND) submission**

On-Track

1-3 INDs per year over next 5 years

- 20+ internal programs in the pipeline
- Expect steady flow of readouts on potentially first-in-class therapeutic antibodies

COPYRIGHT © ABCELLERA

THANK YOU



COPYRIGHT © ABCELLERA